In a randomized clinical trial, Díaz-Luis et al. reported that patients with primary IgA deficiency experienced a significant increase in IgG and IgM levels (IgG at baseline 8.2, after intervention 12.0; IgM at baseline 0.07, after intervention 0.12). This evidence concerns the gene CD40LG and selective IgA deficiency disease.